行情

DRNA

DRNA

Dicerna制药
NASDAQ

实时行情|Nasdaq Last Sale

19.41
-0.91
-4.48%
盘后: 18.50 -0.91 -4.69% 16:45 02/27 EST
开盘
19.92
昨收
20.32
最高
20.28
最低
19.05
成交量
75.39万
成交额
--
52周最高
27.68
52周最低
10.70
市值
13.28亿
市盈率(TTM)
-13.1477
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测DRNA价格均价为31.50,最高价位50.00,最低价为20.00。

EPS

DRNA 新闻

更多
  • 沪指跌幅超3% 美股遭恐慌抛售重挫4%
  • 新浪财经 · 9分钟前
  • 特朗普:美国最终会控制并消灭新冠病毒
  • 环球网 · 1小时前
  • 淘宝经济暖报:100万人围观义乌“云开市”
  • 新浪财经综合 · 1小时前
  • 东京迪士尼乐园宣布因疫情关闭两周
  • 新浪财经 · 2小时前

所属板块

生物技术和医学研究
-2.24%
制药与医学研究
-2.52%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

DRNA 简况

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
展开

微牛提供Dicerna Pharmaceuticals Inc(NASDAQ-DRNA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的DRNA股票新闻,以帮助您做出投资决策。